BrainChild Bio targets deadly pediatric brain cancer with $116M series A
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
BrainChild Bio
Private
Clinical-stage biotech developing CAR-T cell therapies for pediatric brain tumors in the CNS. Spinout from Seattle Children's Hospital.
Company Info
Upcoming Milestones & Key Dates
2026-Q4
Funding/Clinical
$116M Series A pivotal trial initiation
2027-H1
Clinical
BrainChild-01 Phase 1 data update
Clinical Development Pipeline
BrainChild-01
Target: CAR-T cell therapyBrainChild-02
Target: CAR-T cell therapyBrainChild-03
Target: CAR-T cell therapyRecent News
BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T
News from Endpoints News: BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T
Leadership Team
Michael Jensen
Founder & Chief Scientific Officer
James Bagley
CEO